Optimizing Cardiovascular Care With Mineralocorticoid Receptor Antagonists
Mineralocorticoid receptor antagonists (MRAs) block the action of aldosterone at receptors in the kidneys, causing increased sodium and water excretion in exchange for potassium retention. There are 4 treatment groups in the cardiovascular population that have shown benefit with MRA therapy: resista...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Mendoza, Kelly S. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2017transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
6 |
|---|
| Übergeordnetes Werk: |
Enthalten in: The Use of Solicited Publishing by Academic Surgeons - Nguyen, Vi ELSEVIER, 2018, JNP : official journal of the American College of Nurse Practitioner, New York, NY [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:13 ; year:2017 ; number:2 ; pages:156-161 ; extent:6 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.nurpra.2016.11.003 |
|---|
| Katalog-ID: |
ELV035735066 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV035735066 | ||
| 003 | DE-627 | ||
| 005 | 20230625205353.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.nurpra.2016.11.003 |2 doi | |
| 028 | 5 | 2 | |a GBVA2017005000016.pica |
| 035 | |a (DE-627)ELV035735066 | ||
| 035 | |a (ELSEVIER)S1555-4155(16)30665-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.65 |2 bkl | ||
| 100 | 1 | |a Mendoza, Kelly S. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Optimizing Cardiovascular Care With Mineralocorticoid Receptor Antagonists |
| 264 | 1 | |c 2017transfer abstract | |
| 300 | |a 6 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Mineralocorticoid receptor antagonists (MRAs) block the action of aldosterone at receptors in the kidneys, causing increased sodium and water excretion in exchange for potassium retention. There are 4 treatment groups in the cardiovascular population that have shown benefit with MRA therapy: resistant hypertension, post–acute coronary syndromes, heart failure with reduced ejection fraction, and heart failure with preserved ejection fraction. Serum potassium and kidney function should be monitored closely, especially if a patient is on a concomitant angiotensin-converting enzyme inhibitor, an angiotensin II receptor blocker, or direct renin inhibitor therapy. | ||
| 520 | |a Mineralocorticoid receptor antagonists (MRAs) block the action of aldosterone at receptors in the kidneys, causing increased sodium and water excretion in exchange for potassium retention. There are 4 treatment groups in the cardiovascular population that have shown benefit with MRA therapy: resistant hypertension, post–acute coronary syndromes, heart failure with reduced ejection fraction, and heart failure with preserved ejection fraction. Serum potassium and kidney function should be monitored closely, especially if a patient is on a concomitant angiotensin-converting enzyme inhibitor, an angiotensin II receptor blocker, or direct renin inhibitor therapy. | ||
| 650 | 7 | |a potassium-sparing diuretics |2 Elsevier | |
| 650 | 7 | |a heart failure |2 Elsevier | |
| 650 | 7 | |a myocardial infarction |2 Elsevier | |
| 650 | 7 | |a mineralocorticoid receptor antagonists |2 Elsevier | |
| 650 | 7 | |a aldosterone antagonists |2 Elsevier | |
| 650 | 7 | |a resistant hypertension |2 Elsevier | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Nguyen, Vi ELSEVIER |t The Use of Solicited Publishing by Academic Surgeons |d 2018 |d JNP : official journal of the American College of Nurse Practitioner |g New York, NY [u.a.] |w (DE-627)ELV000088234 |
| 773 | 1 | 8 | |g volume:13 |g year:2017 |g number:2 |g pages:156-161 |g extent:6 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.nurpra.2016.11.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.65 |j Chirurgie |q VZ |
| 951 | |a AR | ||
| 952 | |d 13 |j 2017 |e 2 |h 156-161 |g 6 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
k s m ks ksm |
|---|---|
| matchkey_str |
mendozakellys:2017----:piiigadoaclraeihieaootcir |
| hierarchy_sort_str |
2017transfer abstract |
| bklnumber |
44.65 |
| publishDate |
2017 |
| allfields |
10.1016/j.nurpra.2016.11.003 doi GBVA2017005000016.pica (DE-627)ELV035735066 (ELSEVIER)S1555-4155(16)30665-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.65 bkl Mendoza, Kelly S. verfasserin aut Optimizing Cardiovascular Care With Mineralocorticoid Receptor Antagonists 2017transfer abstract 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Mineralocorticoid receptor antagonists (MRAs) block the action of aldosterone at receptors in the kidneys, causing increased sodium and water excretion in exchange for potassium retention. There are 4 treatment groups in the cardiovascular population that have shown benefit with MRA therapy: resistant hypertension, post–acute coronary syndromes, heart failure with reduced ejection fraction, and heart failure with preserved ejection fraction. Serum potassium and kidney function should be monitored closely, especially if a patient is on a concomitant angiotensin-converting enzyme inhibitor, an angiotensin II receptor blocker, or direct renin inhibitor therapy. Mineralocorticoid receptor antagonists (MRAs) block the action of aldosterone at receptors in the kidneys, causing increased sodium and water excretion in exchange for potassium retention. There are 4 treatment groups in the cardiovascular population that have shown benefit with MRA therapy: resistant hypertension, post–acute coronary syndromes, heart failure with reduced ejection fraction, and heart failure with preserved ejection fraction. Serum potassium and kidney function should be monitored closely, especially if a patient is on a concomitant angiotensin-converting enzyme inhibitor, an angiotensin II receptor blocker, or direct renin inhibitor therapy. potassium-sparing diuretics Elsevier heart failure Elsevier myocardial infarction Elsevier mineralocorticoid receptor antagonists Elsevier aldosterone antagonists Elsevier resistant hypertension Elsevier Enthalten in Elsevier Nguyen, Vi ELSEVIER The Use of Solicited Publishing by Academic Surgeons 2018 JNP : official journal of the American College of Nurse Practitioner New York, NY [u.a.] (DE-627)ELV000088234 volume:13 year:2017 number:2 pages:156-161 extent:6 https://doi.org/10.1016/j.nurpra.2016.11.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.65 Chirurgie VZ AR 13 2017 2 156-161 6 045F 610 |
| spelling |
10.1016/j.nurpra.2016.11.003 doi GBVA2017005000016.pica (DE-627)ELV035735066 (ELSEVIER)S1555-4155(16)30665-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.65 bkl Mendoza, Kelly S. verfasserin aut Optimizing Cardiovascular Care With Mineralocorticoid Receptor Antagonists 2017transfer abstract 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Mineralocorticoid receptor antagonists (MRAs) block the action of aldosterone at receptors in the kidneys, causing increased sodium and water excretion in exchange for potassium retention. There are 4 treatment groups in the cardiovascular population that have shown benefit with MRA therapy: resistant hypertension, post–acute coronary syndromes, heart failure with reduced ejection fraction, and heart failure with preserved ejection fraction. Serum potassium and kidney function should be monitored closely, especially if a patient is on a concomitant angiotensin-converting enzyme inhibitor, an angiotensin II receptor blocker, or direct renin inhibitor therapy. Mineralocorticoid receptor antagonists (MRAs) block the action of aldosterone at receptors in the kidneys, causing increased sodium and water excretion in exchange for potassium retention. There are 4 treatment groups in the cardiovascular population that have shown benefit with MRA therapy: resistant hypertension, post–acute coronary syndromes, heart failure with reduced ejection fraction, and heart failure with preserved ejection fraction. Serum potassium and kidney function should be monitored closely, especially if a patient is on a concomitant angiotensin-converting enzyme inhibitor, an angiotensin II receptor blocker, or direct renin inhibitor therapy. potassium-sparing diuretics Elsevier heart failure Elsevier myocardial infarction Elsevier mineralocorticoid receptor antagonists Elsevier aldosterone antagonists Elsevier resistant hypertension Elsevier Enthalten in Elsevier Nguyen, Vi ELSEVIER The Use of Solicited Publishing by Academic Surgeons 2018 JNP : official journal of the American College of Nurse Practitioner New York, NY [u.a.] (DE-627)ELV000088234 volume:13 year:2017 number:2 pages:156-161 extent:6 https://doi.org/10.1016/j.nurpra.2016.11.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.65 Chirurgie VZ AR 13 2017 2 156-161 6 045F 610 |
| allfields_unstemmed |
10.1016/j.nurpra.2016.11.003 doi GBVA2017005000016.pica (DE-627)ELV035735066 (ELSEVIER)S1555-4155(16)30665-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.65 bkl Mendoza, Kelly S. verfasserin aut Optimizing Cardiovascular Care With Mineralocorticoid Receptor Antagonists 2017transfer abstract 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Mineralocorticoid receptor antagonists (MRAs) block the action of aldosterone at receptors in the kidneys, causing increased sodium and water excretion in exchange for potassium retention. There are 4 treatment groups in the cardiovascular population that have shown benefit with MRA therapy: resistant hypertension, post–acute coronary syndromes, heart failure with reduced ejection fraction, and heart failure with preserved ejection fraction. Serum potassium and kidney function should be monitored closely, especially if a patient is on a concomitant angiotensin-converting enzyme inhibitor, an angiotensin II receptor blocker, or direct renin inhibitor therapy. Mineralocorticoid receptor antagonists (MRAs) block the action of aldosterone at receptors in the kidneys, causing increased sodium and water excretion in exchange for potassium retention. There are 4 treatment groups in the cardiovascular population that have shown benefit with MRA therapy: resistant hypertension, post–acute coronary syndromes, heart failure with reduced ejection fraction, and heart failure with preserved ejection fraction. Serum potassium and kidney function should be monitored closely, especially if a patient is on a concomitant angiotensin-converting enzyme inhibitor, an angiotensin II receptor blocker, or direct renin inhibitor therapy. potassium-sparing diuretics Elsevier heart failure Elsevier myocardial infarction Elsevier mineralocorticoid receptor antagonists Elsevier aldosterone antagonists Elsevier resistant hypertension Elsevier Enthalten in Elsevier Nguyen, Vi ELSEVIER The Use of Solicited Publishing by Academic Surgeons 2018 JNP : official journal of the American College of Nurse Practitioner New York, NY [u.a.] (DE-627)ELV000088234 volume:13 year:2017 number:2 pages:156-161 extent:6 https://doi.org/10.1016/j.nurpra.2016.11.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.65 Chirurgie VZ AR 13 2017 2 156-161 6 045F 610 |
| allfieldsGer |
10.1016/j.nurpra.2016.11.003 doi GBVA2017005000016.pica (DE-627)ELV035735066 (ELSEVIER)S1555-4155(16)30665-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.65 bkl Mendoza, Kelly S. verfasserin aut Optimizing Cardiovascular Care With Mineralocorticoid Receptor Antagonists 2017transfer abstract 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Mineralocorticoid receptor antagonists (MRAs) block the action of aldosterone at receptors in the kidneys, causing increased sodium and water excretion in exchange for potassium retention. There are 4 treatment groups in the cardiovascular population that have shown benefit with MRA therapy: resistant hypertension, post–acute coronary syndromes, heart failure with reduced ejection fraction, and heart failure with preserved ejection fraction. Serum potassium and kidney function should be monitored closely, especially if a patient is on a concomitant angiotensin-converting enzyme inhibitor, an angiotensin II receptor blocker, or direct renin inhibitor therapy. Mineralocorticoid receptor antagonists (MRAs) block the action of aldosterone at receptors in the kidneys, causing increased sodium and water excretion in exchange for potassium retention. There are 4 treatment groups in the cardiovascular population that have shown benefit with MRA therapy: resistant hypertension, post–acute coronary syndromes, heart failure with reduced ejection fraction, and heart failure with preserved ejection fraction. Serum potassium and kidney function should be monitored closely, especially if a patient is on a concomitant angiotensin-converting enzyme inhibitor, an angiotensin II receptor blocker, or direct renin inhibitor therapy. potassium-sparing diuretics Elsevier heart failure Elsevier myocardial infarction Elsevier mineralocorticoid receptor antagonists Elsevier aldosterone antagonists Elsevier resistant hypertension Elsevier Enthalten in Elsevier Nguyen, Vi ELSEVIER The Use of Solicited Publishing by Academic Surgeons 2018 JNP : official journal of the American College of Nurse Practitioner New York, NY [u.a.] (DE-627)ELV000088234 volume:13 year:2017 number:2 pages:156-161 extent:6 https://doi.org/10.1016/j.nurpra.2016.11.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.65 Chirurgie VZ AR 13 2017 2 156-161 6 045F 610 |
| allfieldsSound |
10.1016/j.nurpra.2016.11.003 doi GBVA2017005000016.pica (DE-627)ELV035735066 (ELSEVIER)S1555-4155(16)30665-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.65 bkl Mendoza, Kelly S. verfasserin aut Optimizing Cardiovascular Care With Mineralocorticoid Receptor Antagonists 2017transfer abstract 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Mineralocorticoid receptor antagonists (MRAs) block the action of aldosterone at receptors in the kidneys, causing increased sodium and water excretion in exchange for potassium retention. There are 4 treatment groups in the cardiovascular population that have shown benefit with MRA therapy: resistant hypertension, post–acute coronary syndromes, heart failure with reduced ejection fraction, and heart failure with preserved ejection fraction. Serum potassium and kidney function should be monitored closely, especially if a patient is on a concomitant angiotensin-converting enzyme inhibitor, an angiotensin II receptor blocker, or direct renin inhibitor therapy. Mineralocorticoid receptor antagonists (MRAs) block the action of aldosterone at receptors in the kidneys, causing increased sodium and water excretion in exchange for potassium retention. There are 4 treatment groups in the cardiovascular population that have shown benefit with MRA therapy: resistant hypertension, post–acute coronary syndromes, heart failure with reduced ejection fraction, and heart failure with preserved ejection fraction. Serum potassium and kidney function should be monitored closely, especially if a patient is on a concomitant angiotensin-converting enzyme inhibitor, an angiotensin II receptor blocker, or direct renin inhibitor therapy. potassium-sparing diuretics Elsevier heart failure Elsevier myocardial infarction Elsevier mineralocorticoid receptor antagonists Elsevier aldosterone antagonists Elsevier resistant hypertension Elsevier Enthalten in Elsevier Nguyen, Vi ELSEVIER The Use of Solicited Publishing by Academic Surgeons 2018 JNP : official journal of the American College of Nurse Practitioner New York, NY [u.a.] (DE-627)ELV000088234 volume:13 year:2017 number:2 pages:156-161 extent:6 https://doi.org/10.1016/j.nurpra.2016.11.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.65 Chirurgie VZ AR 13 2017 2 156-161 6 045F 610 |
| language |
English |
| source |
Enthalten in The Use of Solicited Publishing by Academic Surgeons New York, NY [u.a.] volume:13 year:2017 number:2 pages:156-161 extent:6 |
| sourceStr |
Enthalten in The Use of Solicited Publishing by Academic Surgeons New York, NY [u.a.] volume:13 year:2017 number:2 pages:156-161 extent:6 |
| format_phy_str_mv |
Article |
| bklname |
Chirurgie |
| institution |
findex.gbv.de |
| topic_facet |
potassium-sparing diuretics heart failure myocardial infarction mineralocorticoid receptor antagonists aldosterone antagonists resistant hypertension |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
The Use of Solicited Publishing by Academic Surgeons |
| authorswithroles_txt_mv |
Mendoza, Kelly S. @@aut@@ |
| publishDateDaySort_date |
2017-01-01T00:00:00Z |
| hierarchy_top_id |
ELV000088234 |
| dewey-sort |
3610 |
| id |
ELV035735066 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV035735066</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625205353.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.nurpra.2016.11.003</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017005000016.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV035735066</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1555-4155(16)30665-1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.65</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Mendoza, Kelly S.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Optimizing Cardiovascular Care With Mineralocorticoid Receptor Antagonists</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Mineralocorticoid receptor antagonists (MRAs) block the action of aldosterone at receptors in the kidneys, causing increased sodium and water excretion in exchange for potassium retention. There are 4 treatment groups in the cardiovascular population that have shown benefit with MRA therapy: resistant hypertension, post–acute coronary syndromes, heart failure with reduced ejection fraction, and heart failure with preserved ejection fraction. Serum potassium and kidney function should be monitored closely, especially if a patient is on a concomitant angiotensin-converting enzyme inhibitor, an angiotensin II receptor blocker, or direct renin inhibitor therapy.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Mineralocorticoid receptor antagonists (MRAs) block the action of aldosterone at receptors in the kidneys, causing increased sodium and water excretion in exchange for potassium retention. There are 4 treatment groups in the cardiovascular population that have shown benefit with MRA therapy: resistant hypertension, post–acute coronary syndromes, heart failure with reduced ejection fraction, and heart failure with preserved ejection fraction. Serum potassium and kidney function should be monitored closely, especially if a patient is on a concomitant angiotensin-converting enzyme inhibitor, an angiotensin II receptor blocker, or direct renin inhibitor therapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">potassium-sparing diuretics</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">heart failure</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">myocardial infarction</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">mineralocorticoid receptor antagonists</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">aldosterone antagonists</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">resistant hypertension</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Nguyen, Vi ELSEVIER</subfield><subfield code="t">The Use of Solicited Publishing by Academic Surgeons</subfield><subfield code="d">2018</subfield><subfield code="d">JNP : official journal of the American College of Nurse Practitioner</subfield><subfield code="g">New York, NY [u.a.]</subfield><subfield code="w">(DE-627)ELV000088234</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:13</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:156-161</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.nurpra.2016.11.003</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.65</subfield><subfield code="j">Chirurgie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">13</subfield><subfield code="j">2017</subfield><subfield code="e">2</subfield><subfield code="h">156-161</subfield><subfield code="g">6</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Mendoza, Kelly S. |
| spellingShingle |
Mendoza, Kelly S. ddc 610 bkl 44.65 Elsevier potassium-sparing diuretics Elsevier heart failure Elsevier myocardial infarction Elsevier mineralocorticoid receptor antagonists Elsevier aldosterone antagonists Elsevier resistant hypertension Optimizing Cardiovascular Care With Mineralocorticoid Receptor Antagonists |
| authorStr |
Mendoza, Kelly S. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000088234 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 44.65 bkl Optimizing Cardiovascular Care With Mineralocorticoid Receptor Antagonists potassium-sparing diuretics Elsevier heart failure Elsevier myocardial infarction Elsevier mineralocorticoid receptor antagonists Elsevier aldosterone antagonists Elsevier resistant hypertension Elsevier |
| topic |
ddc 610 bkl 44.65 Elsevier potassium-sparing diuretics Elsevier heart failure Elsevier myocardial infarction Elsevier mineralocorticoid receptor antagonists Elsevier aldosterone antagonists Elsevier resistant hypertension |
| topic_unstemmed |
ddc 610 bkl 44.65 Elsevier potassium-sparing diuretics Elsevier heart failure Elsevier myocardial infarction Elsevier mineralocorticoid receptor antagonists Elsevier aldosterone antagonists Elsevier resistant hypertension |
| topic_browse |
ddc 610 bkl 44.65 Elsevier potassium-sparing diuretics Elsevier heart failure Elsevier myocardial infarction Elsevier mineralocorticoid receptor antagonists Elsevier aldosterone antagonists Elsevier resistant hypertension |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| hierarchy_parent_title |
The Use of Solicited Publishing by Academic Surgeons |
| hierarchy_parent_id |
ELV000088234 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
The Use of Solicited Publishing by Academic Surgeons |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000088234 |
| title |
Optimizing Cardiovascular Care With Mineralocorticoid Receptor Antagonists |
| ctrlnum |
(DE-627)ELV035735066 (ELSEVIER)S1555-4155(16)30665-1 |
| title_full |
Optimizing Cardiovascular Care With Mineralocorticoid Receptor Antagonists |
| author_sort |
Mendoza, Kelly S. |
| journal |
The Use of Solicited Publishing by Academic Surgeons |
| journalStr |
The Use of Solicited Publishing by Academic Surgeons |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2017 |
| contenttype_str_mv |
zzz |
| container_start_page |
156 |
| author_browse |
Mendoza, Kelly S. |
| container_volume |
13 |
| physical |
6 |
| class |
610 610 DE-600 610 VZ 44.65 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Mendoza, Kelly S. |
| doi_str_mv |
10.1016/j.nurpra.2016.11.003 |
| dewey-full |
610 |
| title_sort |
optimizing cardiovascular care with mineralocorticoid receptor antagonists |
| title_auth |
Optimizing Cardiovascular Care With Mineralocorticoid Receptor Antagonists |
| abstract |
Mineralocorticoid receptor antagonists (MRAs) block the action of aldosterone at receptors in the kidneys, causing increased sodium and water excretion in exchange for potassium retention. There are 4 treatment groups in the cardiovascular population that have shown benefit with MRA therapy: resistant hypertension, post–acute coronary syndromes, heart failure with reduced ejection fraction, and heart failure with preserved ejection fraction. Serum potassium and kidney function should be monitored closely, especially if a patient is on a concomitant angiotensin-converting enzyme inhibitor, an angiotensin II receptor blocker, or direct renin inhibitor therapy. |
| abstractGer |
Mineralocorticoid receptor antagonists (MRAs) block the action of aldosterone at receptors in the kidneys, causing increased sodium and water excretion in exchange for potassium retention. There are 4 treatment groups in the cardiovascular population that have shown benefit with MRA therapy: resistant hypertension, post–acute coronary syndromes, heart failure with reduced ejection fraction, and heart failure with preserved ejection fraction. Serum potassium and kidney function should be monitored closely, especially if a patient is on a concomitant angiotensin-converting enzyme inhibitor, an angiotensin II receptor blocker, or direct renin inhibitor therapy. |
| abstract_unstemmed |
Mineralocorticoid receptor antagonists (MRAs) block the action of aldosterone at receptors in the kidneys, causing increased sodium and water excretion in exchange for potassium retention. There are 4 treatment groups in the cardiovascular population that have shown benefit with MRA therapy: resistant hypertension, post–acute coronary syndromes, heart failure with reduced ejection fraction, and heart failure with preserved ejection fraction. Serum potassium and kidney function should be monitored closely, especially if a patient is on a concomitant angiotensin-converting enzyme inhibitor, an angiotensin II receptor blocker, or direct renin inhibitor therapy. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| container_issue |
2 |
| title_short |
Optimizing Cardiovascular Care With Mineralocorticoid Receptor Antagonists |
| url |
https://doi.org/10.1016/j.nurpra.2016.11.003 |
| remote_bool |
true |
| ppnlink |
ELV000088234 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1016/j.nurpra.2016.11.003 |
| up_date |
2024-07-06T18:20:03.041Z |
| _version_ |
1803854810228719616 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV035735066</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625205353.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.nurpra.2016.11.003</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017005000016.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV035735066</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1555-4155(16)30665-1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.65</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Mendoza, Kelly S.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Optimizing Cardiovascular Care With Mineralocorticoid Receptor Antagonists</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Mineralocorticoid receptor antagonists (MRAs) block the action of aldosterone at receptors in the kidneys, causing increased sodium and water excretion in exchange for potassium retention. There are 4 treatment groups in the cardiovascular population that have shown benefit with MRA therapy: resistant hypertension, post–acute coronary syndromes, heart failure with reduced ejection fraction, and heart failure with preserved ejection fraction. Serum potassium and kidney function should be monitored closely, especially if a patient is on a concomitant angiotensin-converting enzyme inhibitor, an angiotensin II receptor blocker, or direct renin inhibitor therapy.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Mineralocorticoid receptor antagonists (MRAs) block the action of aldosterone at receptors in the kidneys, causing increased sodium and water excretion in exchange for potassium retention. There are 4 treatment groups in the cardiovascular population that have shown benefit with MRA therapy: resistant hypertension, post–acute coronary syndromes, heart failure with reduced ejection fraction, and heart failure with preserved ejection fraction. Serum potassium and kidney function should be monitored closely, especially if a patient is on a concomitant angiotensin-converting enzyme inhibitor, an angiotensin II receptor blocker, or direct renin inhibitor therapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">potassium-sparing diuretics</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">heart failure</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">myocardial infarction</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">mineralocorticoid receptor antagonists</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">aldosterone antagonists</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">resistant hypertension</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Nguyen, Vi ELSEVIER</subfield><subfield code="t">The Use of Solicited Publishing by Academic Surgeons</subfield><subfield code="d">2018</subfield><subfield code="d">JNP : official journal of the American College of Nurse Practitioner</subfield><subfield code="g">New York, NY [u.a.]</subfield><subfield code="w">(DE-627)ELV000088234</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:13</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:156-161</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.nurpra.2016.11.003</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.65</subfield><subfield code="j">Chirurgie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">13</subfield><subfield code="j">2017</subfield><subfield code="e">2</subfield><subfield code="h">156-161</subfield><subfield code="g">6</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.4001417 |